Pay in 4 interest-free payments of $6.00 Learn more
Ships within 48 hours · Estimated delivery Nov 12 - Nov 17
Implications for marketers: Interest in GLP-1s is highest among consumers diagnosed as overweight or obese, but weight loss isnt always what motivates people to use GLP-1s
Regular check-ins allow us to adjust your plan based on how your body responds
.webp)
A 2025 Institute for Clinical and Economic Review (ICER) report notes that weekly GLP-1s like semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) have become more cost-effective over time due to price reductions and proven long-term benefits ( [11] )
This series of phase 3, randomised, double-blind, placebo-controlled clinical trials involved more than 25,000 individuals with overweight or obesity and has extensively demonstrated the efficacy of once-weekly subcutaneous semaglutide 2.4 mg in promoting weight loss [13, 38,39,40,41,42,43,44,45,46]
